ArticleNeural plasticity2026
Prefrontal Cortex 5-HT1A Receptor-Coupled Inwardly Rectifying Potassium Channels Decreased Seizure Susceptibility in Rat Models With Autism Spectrum Disorder.
Article in Neural plasticity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dysregulation of serotonin 1A receptor (5-HT1A), a G protein-coupled inhibitory receptor, is implicated in the pathogenesis of both autism spectrum disorder (ASD) and epilepsy. The prefrontal cortex (PFC) is particularly vulnerable to the factors that affect neuronal and synaptic development, with abnormal PFC development leading to increased epilepsy susceptibility. This study used 8-OH-DPAT to activate PFC 5-HT1A to investigate its role in attenuating epileptic susceptibility in a valproic acid (VPA)-induced rat model of ASD and potential mechanisms involving Kir3 channel-mediated hyperpolarization. Rats were prenatally exposed to VPA to induce autism-like behaviors, and successful induction was verified through behavioral, morphological, and electrophysiological assessments. Neuronal loss, dendritic complexity, and spine density in the PFC were evaluated using Nissl and Golgi staining. Pentylenetetrazol (PTZ) was used to induce chemical kindling for assessing seizure susceptibility in the ASD model. Spontaneous action potential (sAP) and miniature excitatory postsynaptic current (mEPSC) frequencies were electrophysiologically recorded. The selective 5-HT1A receptor (5-HT1AR) agonist 8-OH-DPAT was used to investigate its anticonvulsant effects. ASD rats exhibited significant neuronal loss, reduced dendritic complexity, and lower dendritic spine density in the PFC. The PTZ-treated ASD group showed reduced seizure onset latency, prolonged stage IV seizure duration, and higher seizure incidence, indicating increased susceptibility to epilepsy. Untreated rats displayed reduced sAP and mEPSC frequencies in PFC pyramidal neurons, suggesting E/I imbalance. However, PTZ treatment increased sAP and mEPSC frequencies, reflecting enhanced neuronal excitability. Treatment with 8-OH-DPAT significantly delayed seizure onset, shortened seizure duration, and reduced seizure incidence. Furthermore, 8-OH-DPAT decreased sAP and mEPSC frequencies. These effects were attenuated after applying tertiapin-Q (TQ), underscoring the role of inwardly rectifying potassium (Kir3) channels in mediating 8-OH-DPAT-induced anticonvulsant effects. In conclusion, PFC 5-HT1AR activity alleviated epileptic activity through Kir3 channel-mediated hyperpolarization. These findings highlight 5-HT1ARs and Kir3 channels as promising therapeutic targets for epilepsy associated with ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.